<DOC>
	<DOC>NCT02613871</DOC>
	<brief_summary>This study will evaluate the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) administered for 12 weeks in chronic genotype 1 or 2 HCV infected adults who are co-infected with HBV in Taiwan.</brief_summary>
	<brief_title>Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Coinfection</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<mesh_term>Ledipasvir, sofosbuvir drug combination</mesh_term>
	<criteria>Key Individuals with chronic genotype 1 or 2 HCV and HBV coinfection Individuals must not be taking or require treatment with HBV antiviral therapy at screening. For participants that are HBV treatment experienced, the most recent treatment must have been completed at least 6 months prior to Day 1. Cirrhosis determination by Fibroscan Screening laboratory values within defined thresholds Use of two effective contraception methods if female or male is of childbearing potential Key Current or prior history of clinicallysignificant illness or any other major medical disorder that may interfere with individual's treatment, assessment or compliance with the protocol Pregnant or nursing female Infection with human immunodeficiency virus (HIV) or Hepatitis Delta virus (HDV) Hepatocellular carcinoma (HCC) or other malignancy Current or prior history of clinical hepatic decompensation Note: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>